Abstract 572P
Background
Lung cancer was the leading cause of mortality in 2022, with 38.4% of patients having non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. EGFR tyrosine kinase inhibitors (TKIs) are the first-line treatment for EGFR-mutated NSCLC. A limited number of patients achieved five-year survival. This retrospective study aimed to provide real-world evidence and explore the factors affecting the five-year survival of patients with EGFR-mutated NSCLC.
Methods
This study included patients with EGFR-mutated NSCLC treated in Chang Gung Memorial Hospitals between 2011 and 2016, ensuring at least five years of follow-up or mortality. Odds ratios (ORs) were calculated using univariate and multivariate analyses. A scoring system based on a logistic regression model was designed to evaluate factor weightings on patients’ five-year survival. Their overall survival probability was estimated using the Kaplan-Meier model. The model’s accuracy was assessed using the area under the receiver operating characteristic curve (AUC).
Results
Of 1,873 enrolled patients, 185 were lost to follow-up within five years, leaving 1,787 for analysis. Of patients achieving five-year survival, more were female, age 65 years, had performance scores of 0∼1, no metastases, and adequate objective responses and disease control. A scoring system was developed by assigning points to each prognostic factor associated with increased risk of not achieving five-year survival: age > 65 years (1 point); performance score of 2∼4 (2 points); stage IV disease (1 point); liver (2 points), bone (1 point), or pleura (1 point) metastasis; and poor disease control (2 points). In the Kaplan-Meier model, the estimated five-year survival rate was 39.4%, 13.0%, 7.2%, and 2.2% for the low-risk (0∼1 point), intermediate-risk (2 points), high-risk (3 points), and very-high-risk (4∼10 points) groups, respectively. The prediction model’s AUC was 0.787 (95% CI: 0.752∼0.821), indicating fair accuracy.
Conclusions
We proposed a scoring system based on real-world data for predicting the five-year survival of patients with EGFR-mutated NSCLC treated with EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chang Gung Memorial Hospital (Linkou Branch).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract